Salvage Therapy with Intraoperative Cesium-131 for Recurrent Ovarian Cancer

Recurrent ovarian cancer is considered incurable and the current standard of treatment (surgery and chemotherapy) is palliative. For isolated, localized recurrent tumor, brachytherapy with Cesium-131 is a promising treatment because of its localized radiation yet limited exposure to healthy tissue. Compared to its predecessors, Cs-131 has a very short half-life, allowing for highly localized radiation that decreases toxicity of treatment and convenience for the patient. Our case shows a patient diagnosed with recurrent ovarian cancer metastatic to the right paraaortic odes. The first successful application of Cs-131 brachytherapy was performed with 100% local control without added toxicity. This shows a favorable addition to the current standard of care for highly localized ovarian cancers.